Enzomenib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Enzomenib
- Molecular weight
- 590.74
- Structure (SMILES)
- C=C1C[C@@H]2CC[C@H]1[C@@H](C(=O)N1CCC3(CC1)CN(c1ncncc1Oc1ccc(F)cc1C(=O)N(C(C)C)C(C)C)C3)N2
- dsp 5336
- DSP 5336 [WHO-DD]
- dsp 5336 09 free base
- dsp 5336 who dd
- Dsp-5336
- DSP-5336
- DSP-5336-09 FREE BASE
- enzomenib
- Enzomenib
- enzomenib [INN]
- ENZOMENIB [USAN]
- enzomenib inn
- enzomenib usan
- CAS registry numbers
- 2412555-70-3
- ChEMBL ID
- CHEMBL5314915
- InChIKey
- JQHJEDMMWUIYCE-FVVBACEJSA-N
- PubChem compound IDs
- 146430058
- FDA ingredient codes (UNII)
- VW83Y2JLZ5
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- enzomenib
- Type
- Synthetic organic
- Drug name stem
- -menib
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0004967
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0010643
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018874
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018881
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0019460
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0020076
- Highest recorded phase
- 1
Trial references
- NCT04988555
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 1
- Polar surface area
- 90.9
- Calculated partition coefficient (ALogP)
- 4.79
- Calculated partition coefficient (XLogP)
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 7
- Heavy atoms
- 43
- Molecular formula
- C33H43FN6O3
- Monoisotopic mass
- 590.33806742
- Natural product
- No
- Recorded assays
- 2
- Active assays
- 2
Active assay types
- Confirmatory
Related records
Trials (2)
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
In development for (3)
- Acute lymphoblastic leukemia Phase 1
- Acute myeloid leukemia Phase 1
- Neoplasm Phase 2